December 16, 2024 03:54 PM EST

AstraZeneca is denied full FDA approval of Andexxa following critical advisory meeting

Max Bayer

Pharma Reporter

AstraZeneca said the FDA declined to fully approve its anticoagulant reversal drug Andexxa, less than a month after an advisory committee meeting at which the …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

AstraZeneca is denied full FDA approval of Andexxa following critical advisory meeting

Max Bayer

Pharma Reporter

Sign up to read this article for free.

What Trump’s FTC picks mean for biopharma dealmaking and PBMs

Neurocrine gets FDA go-ahead to treat rare adrenal gland condition

Bicycle Therapeutics stock sinks following release of topline data, post-hoc analyses

Viridian readies for Tepezza rivalry with new Phase 3 data in thyroid eye disease

Roche terminates a Phase 3 Spark gene therapy in hemophilia A

Bristol Myers drops cell therapy pacts with Immatics, Century as part of portfolio review

As­traZeneca is de­nied full FDA ap­proval of An­dexxa fol­low­ing crit­i­cal ad­vi­so­ry meet­ing

Max Bayer

Pharma Reporter

Sign up to read this article for free.

more like this

What Trump’s FTC picks mean for bio­phar­ma deal­mak­ing and PBMs

Neu­ro­crine gets FDA go-ahead to treat rare adren­al gland con­di­tion

Bi­cy­cle Ther­a­peu­tics stock sinks fol­low­ing re­lease of topline da­ta, post-hoc analy­ses

Virid­i­an read­ies for Te­pez­za ri­val­ry with new Phase 3 da­ta in thy­roid eye dis­ease

Roche ter­mi­nates a Phase 3 Spark gene ther­a­py in he­mo­phil­ia A

Bris­tol My­ers drops cell ther­a­py pacts with Im­mat­ics, Cen­tu­ry as part of port­fo­lio re­view

AstraZeneca is denied full FDA approval of Andexxa following critical advisory meeting

What Trump’s FTC picks mean for biopharma dealmaking and PBMs

Neurocrine gets FDA go-ahead to treat rare adrenal gland condition

Bicycle Therapeutics stock sinks following release of topline data, post-hoc analyses

Viridian readies for Tepezza rivalry with new Phase 3 data in thyroid eye disease

Roche terminates a Phase 3 Spark gene therapy in hemophilia A

Bristol Myers drops cell therapy pacts with Immatics, Century as part of portfolio review